- March 10, 2026BARCELONA, Spain I March 10, 2026 I La Merie Publishing announced the publication of the biologics market report for the…
- March 9, 2026Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
- November 10, 2025MUC16: old target revisited with new technologies – a pipeline review STUTTGART, Germany I November 10, 2025 I La Merie…
- November 8, 2025CDH6: clinical PoC of lead anti-CDH6 ADC boosts pipeline – a pipeline review STUTTGART, Germany I November 08, 2025 I…
- November 6, 2025MUC1: an old target accessed with new technologies leading to first signs of clinical activity – a pipeline review STUTTGART,…
- September 25, 2025Claudin 18.2: a clinically validated target and plenty of improvement options with new drug modalities – a pipeline review STUTTGART,…
- September 24, 2025PD-L1 and 4-1BB (CD137): promising immuno-oncology therapy combination to overcome on-target-off-tumor toxicity – a pipeline review STUTTGART, Germany I September…
- September 23, 2025CD47 and SIRPα: next generation inhibitors to show clinical benefit – a pipeline review STUTTGART, Germany I September 23, 2025…
- September 22, 2025Complement C5: a commercially successful and clinically effective treatment of C5 mediated diseases – a pipeline review STUTTGART, Germany I…
- September 9, 2025IL-6 and IL-6R: hot targets for underexploited indications – a pipeline review STUTTGART, Germany I September 09, 2025 I La…
